In Graves disease, selenium supplementation might lead to faster remission of hyperthyroidism and improved quality of life and eye involvement in patients with mild thyroid eye disease
On September 19, 2025, the FDA issued Import Alert 66-80, which authorizes field staff to detain without physical examination shipments of GLP-1 active pharmaceutical ingredients (APIs) from manufacturers not included on its newly established Green List.[1] This action follows FDAs September 5 th announcement of the Green List initiative to curb illegal imports of semaglutide, tirzepatide, and other corresponding APIs.[2] Together, the Green List and Import Alert form FDAs most aggressive enforcement measures to date against GLP-1 imports
10.1093/jexbot/53.372.1305 122 ShimaokaT.YokotaA.MiyakeC
Early phase II studies in older adults with sarcopenia showed increases in lean mass and, in slower walkers, improvements in gait speed and 6-minute walk distance [62]
Starting with semaglutide injection ($189/month) offers an affordable entry point